Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure.

@article{Boerrigter2003CardiorenalAH,
  title={Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure.},
  author={Guido Boerrigter and Lisa C. Costello-Boerrigter and Alessandro Cataliotti and Toshihiro Tsuruda and Gail J. Harty and Harald Lapp and J. -P. Stasch and John C Jr. Burnett},
  journal={Circulation},
  year={2003},
  volume={107 5},
  pages={
          686-9
        }
}
BACKGROUND BAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. To date, its therapeutic actions in congestive heart failure (CHF) remain undefined. We characterized the cardiorenal actions of intravenous BAY 41-2272 in a canine model of CHF and compared it to nitroglycerin (NTG). METHODS AND RESULTS CHF was induced by rapid ventricular pacing for 10 days… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

Natriuretic peptides and therapeutic applications

  • Heart Failure Reviews
  • 2007
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Breakthrough in heart failure with preserved ejection fraction: are we there yet?

  • The Korean journal of internal medicine
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 10 REFERENCES

Identification of the enzymatic mechanism of nitroglycerin bioactivation.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2002

Similar Papers

Loading similar papers…